share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外國發行人報告
美股sec公告 ·  04/24 07:08
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced the enrollment of the first patient in the ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment. The trial is evaluating RHB-107 (upamostat), a novel oral antiviral, and is supported by the U.S. Department of Defense among other non-dilutive external sources. The study, which is expected to conclude by the end of 2024, is being conducted across multiple countries including the U.S., Thailand, Ivory Coast, South Africa, and Uganda. RHB-107 has previously shown promising results in a U.S. Phase 2 study, with a significant reduction in COVID-19 hospitalizations and new severe symptoms. The drug is host-directed and is expected to be effective against viral variants due to...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced the enrollment of the first patient in the ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment. The trial is evaluating RHB-107 (upamostat), a novel oral antiviral, and is supported by the U.S. Department of Defense among other non-dilutive external sources. The study, which is expected to conclude by the end of 2024, is being conducted across multiple countries including the U.S., Thailand, Ivory Coast, South Africa, and Uganda. RHB-107 has previously shown promising results in a U.S. Phase 2 study, with a significant reduction in COVID-19 hospitalizations and new severe symptoms. The drug is host-directed and is expected to be effective against viral variants due to its mechanism of action. RedHill's COO, Gilead Raday, highlighted the potential of RHB-107 to provide an additional treatment option for early COVID-19 alongside existing treatments like Paxlovid. The company is also progressing with opaganib, another oral drug, for pandemic preparedness, including Acute Radiation Syndrome, in collaboration with the U.S. National Institutes of Health.
專業生物製藥公司RedHill Biopharma Ltd. 宣佈ACESO PROTECT跨國平台試驗招募首位患者進行早期 COVID-19 門診治療。該試驗正在評估一種新型口服抗病毒藥物 RHB-107（upamostat），並得到了美國國防部以及其他非稀釋性外部來源的支持。該研究預計將於2024年底結束，正在包括美國、泰國、科特迪瓦、南非和烏干達在內的多個國家進行。RHB-107 此前在美國一項二期研究中顯示出令人鼓舞的結果，COVID-19 住院人數顯著減少，出現了新的嚴重症狀。該藥物以宿主爲導向，由於其作用機制，有望對病毒變異有效。RedHill 的首席運營官吉利德·雷迪強調，除了 Paxlovid 等現有療法，RHB-107 有可能爲早期 COVID-19 提供額外的治療選擇。該公司還與美國國立衛生研究院合作開發另一種口服藥物奧帕加尼布，用於防備疫情，包括急性輻射綜合症。
專業生物製藥公司RedHill Biopharma Ltd. 宣佈ACESO PROTECT跨國平台試驗招募首位患者進行早期 COVID-19 門診治療。該試驗正在評估一種新型口服抗病毒藥物 RHB-107（upamostat），並得到了美國國防部以及其他非稀釋性外部來源的支持。該研究預計將於2024年底結束，正在包括美國、泰國、科特迪瓦、南非和烏干達在內的多個國家進行。RHB-107 此前在美國一項二期研究中顯示出令人鼓舞的結果，COVID-19 住院人數顯著減少，出現了新的嚴重症狀。該藥物以宿主爲導向，由於其作用機制，有望對病毒變異有效。RedHill 的首席運營官吉利德·雷迪強調，除了 Paxlovid 等現有療法，RHB-107 有可能爲早期 COVID-19 提供額外的治療選擇。該公司還與美國國立衛生研究院合作開發另一種口服藥物奧帕加尼布，用於防備疫情，包括急性輻射綜合症。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息